Please see the below link.
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
https://www.prnewswire.com/news-releases/first-hbv-patient-dosed-in-phase-iia-clinical-trial-of-asc22-a-subcutaneously-administered-pd-l1-antibody-301112931.html